Roche’s TIGIT results have positive readthrough to Arcus, says BTIG

BTIG contends that leaked data that suggest that the atezo monotherapy arm overperformed in the Skyscraper-01 trial compared to the Cityscape trial “is not a surprise,” adding that Roche’s (RHHBY) data “should provide more confidence to investors” in Arcus Biosciences’ (RCUS) TIGIT franchise. The firm’s recent discussions with a key opinion leader suggest that Keytruda’s real-world efficacy is comparable to the clinical trial results that led to its approval and the KOL also mentioned that “he doesn’t expect Roche’s OS readout to be practice-changing,” said the analyst, who has a Buy rating and $70 price target on Arcus shares.